Mercado Bitcoin, Brazil's largest crypto exchange, confirmed a security breach after over $40 million in suspicious transfers were flagged by blockchain security firm Hypernative. The transfers spanned about ten blockchain networks and occurred within a short time window early November 2, 2026. As a precaution, Mercado Bitcoin temporarily suspended deposits and withdrawals while investigating the incident. The exchange assures customers that no data was leaked and there is no harm to client assets, but it has yet to clarify if any customer funds were lost. The situation highlights the growing role of third-party monitoring and regulatory oversight in Brazil's evolving crypto market.
Brazil's largest crypto exchange Mercado Bitcoin's security incident provides context for cryptocurrency market activity. For readers following crypto markets, here is Pluang's snapshot as of Nov 02, 2026 20:43 WIB: out of 50 major cryptocurrencies priced on Pluang, 8 rose and 41 fell. Notable movers include LUNC (Terra Classic) at Rp0,75 with a -4.85% change and a typical hold time of 196 days, CRV (Curve DAO Token) at Rp4.969 down 4.46%, and AAVE (Aave) at Rp2.396.301 down 4.24%, with Pluang order activity showing a majority selling trend for these tokens.
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
UroGen Pharma has dosed the first patient in a Phase 1 trial testing UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial aims to evaluate the safety and tolerability of UGN-501 administered directly in...
